Dexcom DXCM Q2 2026: 15% EPS Beat and a Major New Market Opens Up
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Dexcom crushed earnings with a 15% EPS beat and raised full-year guidance as positive results from its CONNECT trial opened a massive new market: type 2 diabetes patients not using insulin. The breakthrough signals CGM adoption is accelerating well beyond its traditional insulin-dependent base, with U.S. revenue up 11% and international revenue surging 19%.
Continue ReadingShow less
Dexcom reported Q2 2026 earnings per share of $0.70, clearing the consensus estimate of $0.61 by roughly 15%. Revenue came in at $1.308 billion, also ahead of the $1.290 billion estimate. The top-line growth was geographically broad: U.S. revenue rose 11% while international revenue surged 19%, pointing to durable demand well beyond any single region.
The bigger story is what the CONNECT trial results mean for Dexcom's addressable market. Positive data from the trial opens the door to continuous glucose monitoring for type 2 diabetes patients who are not using insulin — a population that dwarfs the insulin-dependent base the company has historically served. Management raised full-year guidance off the back of these results, signaling confidence that the trial outcome can translate into real commercial volume.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
Dexcom's EPS trajectory over the past several quarters adds further context. After a soft Q4 2024 miss and a near-miss in Q1 2025, the company has now beaten estimates in five of the last six reported periods, with Q1 2026 delivering a particularly sharp beat of $0.56 reported against a $0.47 estimate. The Q2 2026 result extends that momentum at a higher absolute earnings level than any prior quarter in the comparison set.
Mentioned: DXCM